- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.70 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x NAG- FUC: alpha-L-fucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 2 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x MBT: 3,7-BIS(DIMETHYLAMINO)PHENOTHIAZIN-5-IUM(Non-covalent)
- 2 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 30 x SO4: SULFATE ION(Non-functional Binders)
SO4.5: 3 residues within 4Å:- Chain A: S.237, A.239, R.243
Ligand excluded by PLIPSO4.6: 4 residues within 4Å:- Chain A: K.346, N.382, N.383, G.384
Ligand excluded by PLIPSO4.7: 3 residues within 4Å:- Chain A: H.513, Q.514
- Chain B: M.379
Ligand excluded by PLIPSO4.8: 4 residues within 4Å:- Chain A: P.106, K.107, S.108, T.109
Ligand excluded by PLIPSO4.9: 4 residues within 4Å:- Chain A: H.406, N.409, N.525, Q.526
Ligand excluded by PLIPSO4.10: 5 residues within 4Å:- Chain A: N.424, H.425, N.506, T.507, E.508
Ligand excluded by PLIPSO4.11: 3 residues within 4Å:- Chain A: T.459, A.460, E.461
Ligand excluded by PLIPSO4.12: 5 residues within 4Å:- Chain A: P.21, V.22, L.23, K.133, Y.134
Ligand excluded by PLIPSO4.13: 6 residues within 4Å:- Chain A: R.289, S.359, V.360, P.361, H.362, H.398
Ligand excluded by PLIPSO4.14: 2 residues within 4Å:- Chain A: P.433, E.434
Ligand excluded by PLIPSO4.15: 6 residues within 4Å:- Chain A: Q.68, M.90, S.91, E.92, D.93, P.271
Ligand excluded by PLIPSO4.16: 3 residues within 4Å:- Chain A: D.342, S.343, E.344
Ligand excluded by PLIPSO4.17: 2 residues within 4Å:- Chain A: S.490, K.491
Ligand excluded by PLIPSO4.18: 4 residues within 4Å:- Chain A: R.220, R.221, Q.318, N.416
Ligand excluded by PLIPSO4.19: 1 residues within 4Å:- Chain A: N.382
Ligand excluded by PLIPSO4.24: 3 residues within 4Å:- Chain B: S.237, A.239, R.243
Ligand excluded by PLIPSO4.25: 4 residues within 4Å:- Chain B: K.346, N.382, N.383, G.384
Ligand excluded by PLIPSO4.26: 3 residues within 4Å:- Chain A: M.379
- Chain B: H.513, Q.514
Ligand excluded by PLIPSO4.27: 4 residues within 4Å:- Chain B: P.106, K.107, S.108, T.109
Ligand excluded by PLIPSO4.28: 4 residues within 4Å:- Chain B: H.406, N.409, N.525, Q.526
Ligand excluded by PLIPSO4.29: 5 residues within 4Å:- Chain B: N.424, H.425, N.506, T.507, E.508
Ligand excluded by PLIPSO4.30: 3 residues within 4Å:- Chain B: T.459, A.460, E.461
Ligand excluded by PLIPSO4.31: 5 residues within 4Å:- Chain B: P.21, V.22, L.23, K.133, Y.134
Ligand excluded by PLIPSO4.32: 6 residues within 4Å:- Chain B: R.289, S.359, V.360, P.361, H.362, H.398
Ligand excluded by PLIPSO4.33: 2 residues within 4Å:- Chain B: P.433, E.434
Ligand excluded by PLIPSO4.34: 6 residues within 4Å:- Chain B: Q.68, M.90, S.91, E.92, D.93, P.271
Ligand excluded by PLIPSO4.35: 3 residues within 4Å:- Chain B: D.342, S.343, E.344
Ligand excluded by PLIPSO4.36: 2 residues within 4Å:- Chain B: S.490, K.491
Ligand excluded by PLIPSO4.37: 4 residues within 4Å:- Chain B: R.220, R.221, Q.318, N.416
Ligand excluded by PLIPSO4.38: 1 residues within 4Å:- Chain B: N.382
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Dym, O. et al., The impact of crystallization conditions on structure-based drug design: A case study on the methylene blue/acetylcholinesterase complex. Protein Sci. (2016)
- Release Date
- 2016-03-30
- Peptides
- Acetylcholinesterase: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
A
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.70 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x NAG- FUC: alpha-L-fucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 2 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x MBT: 3,7-BIS(DIMETHYLAMINO)PHENOTHIAZIN-5-IUM(Non-covalent)
- 2 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 30 x SO4: SULFATE ION(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Dym, O. et al., The impact of crystallization conditions on structure-based drug design: A case study on the methylene blue/acetylcholinesterase complex. Protein Sci. (2016)
- Release Date
- 2016-03-30
- Peptides
- Acetylcholinesterase: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
A